Articles by So Yeon Kim, MD
Face-Off: Award Presentations and Event Conclusion
ByJia Luo, MD,Narjust Florez, MD,Justin Gainor, MD,Scott J. Swanson, MD,Anne Chiang, MD ,Roy S. Herbst, MD, PhD,So Yeon Kim, MD,Justin Blasberg, MD, MPH, FACS Judy concludes the event and presents the awards.
Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic NSCLC
ByJia Luo, MD,Narjust Florez, MD,Justin Gainor, MD,Scott J. Swanson, MD,Anne Chiang, MD ,Roy S. Herbst, MD, PhD,So Yeon Kim, MD,Justin Blasberg, MD, MPH, FACS A debate presented on liquid biopsy versus tissue biopsy to determine front line therapy in metastatic NSCLC.
Association Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC
ByJia Luo, MD,Narjust Florez, MD,Justin Gainor, MD,Scott J. Swanson, MD,Anne Chiang, MD ,Roy S. Herbst, MD, PhD,So Yeon Kim, MD,Justin Blasberg, MD, MPH, FACS Dr. Florez leads the discussion on the association between Medicaid insurance, biomarker testing, and the outcomes in patients with advanced NSCLC.
Amivantamab in EGFR Exon 20 Insertion Mutated NSCLC Progression on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase 1 Study
ByJia Luo, MD,Narjust Florez, MD,Justin Gainor, MD,Scott J. Swanson, MD,Anne Chiang, MD ,Roy S. Herbst, MD, PhD,So Yeon Kim, MD,Justin Blasberg, MD, MPH, FACS Dr. Herbst discusses the CHRYSALIS Phase 1 trial.
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA NSCLC: Updated Results From the Phase III Randomized ADAURA Trial
ByJia Luo, MD,Narjust Florez, MD,Justin Gainor, MD,Scott J. Swanson, MD,Anne Chiang, MD ,Roy S. Herbst, MD, PhD,So Yeon Kim, MD,Justin Blasberg, MD, MPH, FACS An overview of results from the phase III randomized ADAURA Trial.
Brigatinib Versus Crizotinib in ALK Inhibitor-Naïve Advanced ALK-Positive NSCLC: Results on Phase 3 ALTA-1L Trial
ByJia Luo, MD,Narjust Florez, MD,Justin Gainor, MD,Scott J. Swanson, MD,Anne Chiang, MD ,Roy S. Herbst, MD, PhD,So Yeon Kim, MD,Justin Blasberg, MD, MPH, FACS A review of Brigatinib versus crizotinib in ALK inhibitor-naïve advanced ALK-positive NSCLC.
KRYSTAL-1: Two Year Follow Up of Adagrasib Monotherapy in Patients With Advanced/Metastatic KRAS G12C Mutated NSCLC
ByJia Luo, MD,Narjust Florez, MD,Justin Gainor, MD,Scott J. Swanson, MD,Anne Chiang, MD ,Roy S. Herbst, MD, PhD,So Yeon Kim, MD,Justin Blasberg, MD, MPH, FACS A review of adagrasib in the KRYSTAL-1 trial in patients with NSCLC.
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC from the Phase III CROWN Study
ByJia Luo, MD,Narjust Florez, MD,Justin Gainor, MD,Scott J. Swanson, MD,Anne Chiang, MD ,Roy S. Herbst, MD, PhD,So Yeon Kim, MD,Justin Blasberg, MD, MPH, FACS A discussion on the Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC: Phase III CROWN Study
Long Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients with Pretreated KRAS G12C-Mutated NSCLC
ByJia Luo, MD,Narjust Florez, MD,Justin Gainor, MD,Scott J. Swanson, MD,Anne Chiang, MD ,Roy S. Herbst, MD, PhD,So Yeon Kim, MD,Justin Blasberg, MD, MPH, FACS The outcomes of the use of Sotorasib in patients with pretreated KRAS G12C mutated NSCLC.
Face-Off: Introduction of the Non-Small Lung Cancer (NSCLC) Debate
ByJia Luo, MD,Narjust Florez, MD,Justin Gainor, MD,Scott J. Swanson, MD,Anne Chiang, MD ,Roy S. Herbst, MD, PhD,So Yeon Kim, MD,Justin Blasberg, MD, MPH, FACS Highlight on the debate format, speakers, and direction to support the discussion.
